Cipla Ltd has launched the generic version of anti-hepatitis drug Ledipasvir-Sofosbuvir in the domestic market. The drug is used for treating hepatitis C virus. About 12-18 million Indians are suffering from the disease while globally the number of patients is about 185 million. Last year, pharma company Gilead Sciences signed non-exclusive licencing agreements with seven companies including Cipla for manufacture and distribution of the drug in India. Cipla also announced the launch of a patient support programme to create awareness among people and to cater to existing patients.
Company Profile : Cipla Ltd
Leave a Reply